A new clinical trial for a potential early treatment of Covid-19 launched in Scotland – and researchers hope it may help “kill off” the virus in affected patients.
More than 300 coronavirus patients will be invited to join the research study into the effectiveness of the antiviral drug favipiravir.
NHS Greater Glasgow and Clyde is the first place in Scotland to have access to the Japanese-manufactured drug, which inhibits viral RNA, helping to stop the virus from replicating.
The health board said it has shown early promise in China and Japan, appearing to alleviate some symptoms.
The joint study between the health board and the University of Glasgow, named Glasgow Early Treatment Arm Favipiravir (Getafix), will assess the drug’s effectiveness in stopping symptoms and reducing recovery time.
Professor Rob Jones, chief investigator of the study and director of the Cancer Research UK Clinical Trials Unit in Glasgow, which is organising the trial, said: “Covid-19 as a disease few of us had even heard of before the spring.
“Although hopes are high ongoing vaccine trials will help prevent infection, this trial aims to improve current treatment for those unlucky enough to contract it.
“With the Getafix trial, we will be rapidly looking at whether this antiviral treatment may help kill off the virus in those affected and prevent more serious complications.”
Focusing on patients with milder symptoms who have a higher risk of these becoming more serious, the treatment must begin within four days of a positive Covid-19 swab test and the antiviral tablets can be taken at home as well as in hospital.
Half of the patients involved will receive the drug twice a day for 10 days alongside standard treatment, with the other half receiving standard treatment for comparison.